1. Medicines
  2. Cardio-Metabolic
  3. LEQVIO®▼ (inclisiran)
  4. Contact us

Prescribing information

 

LEQVIO®▼ (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2,3

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

 

For full safety information, please refer to the GB and NI Summary of Product Characteristics.

 

Speak to a member of the Novartis marketing team inclisiran

Rate this content: 
No votes yet

Speak to a member of the Novartis marketing team

Please complete this form to be contacted by a member of the Novartis marketing team. For medical information, please contact our Medical Information team by email.

Fields marked * below are mandatory.

Your information will be used to put you in contact with a member of the Novartis marketing team and handled in accordance with our Privacy Notice.

UK | December 2023 | 112311-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com